MK-677 vs Sermorelin
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Ibutamoren, Nutrobal
MK-677 (ibutamoren) is not actually a peptide, it is a small, orally active non-peptide molecule that mimics ghrelin, your hunger and growth-hormone hormone. Taken as a daily pill, it reliably pushes up growth hormone and IGF-1 levels, which is why it is popular for muscle and recovery. It has been through real human trials but was never approved as a drug, and the trials that mattered most for older adults and Alzheimer's came up short.
Also: Geref, GRF 1-29
Sermorelin is a 29-amino-acid fragment of human growth hormone-releasing hormone (GHRH), and it is the shortest piece of GHRH that still works fully. It asks the pituitary to make and release its own growth hormone rather than injecting GH itself. It was once an FDA-approved drug for diagnosing and treating growth hormone deficiency in children, but the manufacturer pulled it from the market in 2008, so today it is available mainly through compounding pharmacies for off-label use.
Key Comparison Insights
- Both peptides belong to the Growth Hormone category, suggesting similar primary applications.
- MK-677 has stronger research evidence (Human Trials) compared to Sermorelin (Animal Studies).
Detailed Comparison
| Attribute | MK-677 | Sermorelin |
|---|---|---|
| Category | Growth Hormone | Growth Hormone |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | MK-677 is a selective agonist of the growth hormone secretagogue receptor (GHS-R1a), the same receptor the hormone ghrelin binds. By activating that receptor in the pituitary and hypothalamus, it triggers pulses of growth hormone release, which in turn raises IGF-1 (insulin-like growth factor 1) from the liver. Because it copies ghrelin, it also tends to increase appetite, and it can nudge up cortisol levels too. The effect is sustained because it is long-acting and orally available, unlike injectable peptides that mimic ghrelin or growth-hormone-releasing hormone. | Sermorelin copies the first 29 amino acids of natural GHRH and binds the GHRH receptor on the anterior pituitary, which is the body's normal on-switch for growth hormone production. Activating that receptor tells the pituitary to synthesize and release GH in pulses. A useful safety feature falls out of this design: because the pituitary still answers to its own inhibitory hormone somatostatin, the GH rise stays under negative-feedback control, which makes a true overdose of GH much harder to produce than with injected recombinant GH. |
| Common Dosing | 10-25 mg daily Once daily, often before bed | 200-500 mcg before bed Once daily, typically before bed |
| Administration | Oral | Subcutaneous injection at bedtime |
| Typical Duration | 8-12 weeks or longer | 3-6 months typical |
| Best Time to Take | Before bed | Before bed (fasted) |
Possible Side Effects May vary by individual |
|
|
| Research Summary | MK-677 has unusually good human data for a compound sold in the gray market, and the data is a mix of clear wins and clear failures. In a one-year randomized trial of 65 healthy older adults (Annals of Internal Medicine, 2008), 25 mg daily raised IGF-1 and increased fat-free mass, basically lean tissue, though much of the early body-weight gain was water and the functional strength benefits were not impressive. In Alzheimer's disease, a large 563-patient, 12-month randomized trial (Neurology, 2008) confirmed it raised IGF-1 but did nothing to slow cognitive decline. Across studies the consistent downsides are increased appetite, fluid retention, and reduced insulin sensitivity (higher blood sugar). So the muscle-and-IGF-1 effect is real and well documented, but MK-677 failed its biggest disease trials, remains unapproved, and is banned in sport by WADA. | Sermorelin has a real clinical pedigree, unlike many gray-market peptides. The FDA approved it in 1990 as a diagnostic for GH deficiency and in 1997 for treating idiopathic GH deficiency in children with growth failure, after studies showed about six months of daily injections increased GH release and growth velocity. Published work found intravenous sermorelin is a relatively specific test for GH deficiency with few false positives, and once-daily subcutaneous dosing promoted growth in some GH-deficient prepubertal children. Where the evidence gets thin is the popular adult anti-aging use: a 2006 editorial argued sermorelin is a smarter way to address age-related GH decline than recombinant GH, but it openly conceded that few long-term clinical studies exist. The drug was discontinued commercially in 2008 for business reasons, not safety, so current adult use rests on compounded product and limited modern trial data. |
Frequently Asked Questions: MK-677 vs Sermorelin
What is the difference between MK-677 and Sermorelin?
MK-677 is a growth hormone peptide that mk-677 (ibutamoren) is not actually a peptide, it is a small, orally active non-peptide molecule that mimics ghrelin, your hunger and growth-hormone hormone. taken as a daily pill, it reliably pushes up growth hormone and igf-1 levels, which is why it is popular for muscle and recovery. it has been through real human trials but was never approved as a drug, and the trials that mattered most for older adults and alzheimer's came up short. Sermorelin is a growth hormone peptide that sermorelin is a 29-amino-acid fragment of human growth hormone-releasing hormone (ghrh), and it is the shortest piece of ghrh that still works fully. it asks the pituitary to make and release its own growth hormone rather than injecting gh itself. it was once an fda-approved drug for diagnosing and treating growth hormone deficiency in children, but the manufacturer pulled it from the market in 2008, so today it is available mainly through compounding pharmacies for off-label use. The main differences lie in their mechanisms of action and clinical applications.
Which is better, MK-677 or Sermorelin?
Neither is universally "better" - the choice depends on your specific goals. MK-677 is typically used for growth hormone purposes, while Sermorelin is used for growth hormone. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can MK-677 and Sermorelin be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using MK-677 and Sermorelin together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.